2/23
04:41 pm
iron
Disc Medicine to Seek Traditional FDA Approval for Bitopertin After EPP CRL; APOLLO Data Due Q4 [Yahoo! Finance]
Low
Report
Disc Medicine to Seek Traditional FDA Approval for Bitopertin After EPP CRL; APOLLO Data Due Q4 [Yahoo! Finance]
2/19
08:06 pm
iron
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
2/19
12:30 pm
iron
Disc Medicine: Downgrading As CRL Puts APOLLO Study Into Question [Seeking Alpha]
Low
Report
Disc Medicine: Downgrading As CRL Puts APOLLO Study Into Question [Seeking Alpha]
2/19
05:35 am
iron
Disc Medicine (IRON) Valuation Check After FDA Complete Response Letter On Lead Bitopertin Program [Yahoo! Finance]
Low
Report
Disc Medicine (IRON) Valuation Check After FDA Complete Response Letter On Lead Bitopertin Program [Yahoo! Finance]
2/17
04:58 pm
iron
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
2/17
10:58 am
iron
Disc Medicine (NASDAQ:IRON) was given a new $110.00 price target on by analysts at Stifel Nicolaus.
Medium
Report
Disc Medicine (NASDAQ:IRON) was given a new $110.00 price target on by analysts at Stifel Nicolaus.
2/17
10:42 am
iron
Disc Medicine After The CRL: Risk Now Rests On APOLLO [Seeking Alpha]
Medium
Report
Disc Medicine After The CRL: Risk Now Rests On APOLLO [Seeking Alpha]
2/17
10:04 am
iron
Disc Medicine (NASDAQ:IRON) was given a new $125.00 price target on by analysts at Cantor Fitzgerald.
Medium
Report
Disc Medicine (NASDAQ:IRON) was given a new $125.00 price target on by analysts at Cantor Fitzgerald.
2/17
10:04 am
iron
Disc Medicine (NASDAQ:IRON) was given a new $75.00 price target on by analysts at Morgan Stanley.
Medium
Report
Disc Medicine (NASDAQ:IRON) was given a new $75.00 price target on by analysts at Morgan Stanley.
2/17
09:41 am
iron
Disc Medicine (NASDAQ:IRON) had its price target lowered by analysts at Wells Fargo & Company from $109.00 to $78.00. They now have an "overweight" rating on the stock.
Medium
Report
Disc Medicine (NASDAQ:IRON) had its price target lowered by analysts at Wells Fargo & Company from $109.00 to $78.00. They now have an "overweight" rating on the stock.
2/17
09:41 am
iron
Disc Medicine (NASDAQ:IRON) had its price target lowered by analysts at BMO Capital Markets from $120.00 to $100.00. They now have an "outperform" rating on the stock.
Medium
Report
Disc Medicine (NASDAQ:IRON) had its price target lowered by analysts at BMO Capital Markets from $120.00 to $100.00. They now have an "outperform" rating on the stock.
2/17
09:41 am
iron
Disc Medicine (NASDAQ:IRON) had its price target lowered by analysts at Wedbush from $110.00 to $88.00. They now have an "outperform" rating on the stock.
Medium
Report
Disc Medicine (NASDAQ:IRON) had its price target lowered by analysts at Wedbush from $110.00 to $88.00. They now have an "outperform" rating on the stock.
2/17
08:53 am
iron
Disc Medicine to pursue traditional U.S. approval after FDA rejects new fast-track route [Yahoo! Finance]
High
Report
Disc Medicine to pursue traditional U.S. approval after FDA rejects new fast-track route [Yahoo! Finance]
2/16
07:08 am
iron
FDA issues complete response letter to Disc Medicine's bitopertin NDA [Yahoo! Finance]
High
Report
FDA issues complete response letter to Disc Medicine's bitopertin NDA [Yahoo! Finance]
2/13
03:28 pm
iron
US FDA declines to approve Disc Medicine's rare disease drug [Yahoo! Finance]
Medium
Report
US FDA declines to approve Disc Medicine's rare disease drug [Yahoo! Finance]
2/13
03:04 pm
iron
Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP
High
Report
Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP
2/12
06:51 pm
iron
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
High
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
2/3
01:10 pm
iron
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
1/29
10:00 am
iron
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
1/27
12:33 pm
iron
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Disc Medicine, Inc. – IRON
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Disc Medicine, Inc. – IRON
1/15
02:09 pm
iron
Disc Medicine (NASDAQ:IRON) had its "overweight" rating reaffirmed by analysts at UBS Group AG.
Low
Report
Disc Medicine (NASDAQ:IRON) had its "overweight" rating reaffirmed by analysts at UBS Group AG.
1/15
02:09 pm
iron
Disc Medicine (NASDAQ:IRON) had its "market perform" rating reaffirmed by analysts at Raymond James Financial, Inc..
Low
Report
Disc Medicine (NASDAQ:IRON) had its "market perform" rating reaffirmed by analysts at Raymond James Financial, Inc..
1/15
11:15 am
iron
Disc Medicine (NASDAQ:IRON) had its "outperform" rating reaffirmed by analysts at Wedbush.
Low
Report
Disc Medicine (NASDAQ:IRON) had its "outperform" rating reaffirmed by analysts at Wedbush.
1/12
04:42 pm
iron
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer [Yahoo! Finance]
Medium
Report
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer [Yahoo! Finance]
1/12
04:30 pm
iron
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer
Medium
Report
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer